Journal article
Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab
Abstract
INTRODUCTION: Cardiotoxicity, manifest by reduced left ventricular ejection fraction (LVEF), is the most common reason for the premature discontinuation of trastuzumab. While permissive cardiotoxicity (where mild cardiotoxicity is accepted to enable ongoing trastuzumab) has been shown feasible, the longer-term outcomes are unknown. We aimed to study the intermediate-term clinical outcomes of patients who underwent permissive cardiotoxicity.
Authors
Zhou S; Cirne F; Chow J; Zereshkian A; Bordeleau L; Dhesy-Thind S; Ellis PM; Mukherjee SD; Aghel N; Leong DP
Journal
The Oncologist, Vol. 28, No. 9, pp. e712–e722
Publisher
Oxford University Press (OUP)
Publication Date
September 7, 2023
DOI
10.1093/oncolo/oyad086
ISSN
1083-7159